| Name | Title | Contact Details |
|---|
Genprex (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes. Genprex`s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
Omni Environmental Services is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmagen purifies and distributes safe drinking water through its chain of open water shops in Pakistan, where water contamination is a major challenge.